Tci Wealth Advisors, Inc. Corvus Pharmaceuticals, Inc. Transaction History

Tci Wealth Advisors, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$0.74 - $1.04 $222 - $312	-300 Reduced 37.5%	500 $0
Q2 2022 Jul 19, 2022	BUY	$0.87 - $2.03 $348 - $811	400 Added 100.0%	800 $1,000
Q4 2021 Jan 24, 2022	BUY	$2.34 - $5.31 $234 - $531	100 Added 33.33%	400 $1,000
Q3 2021 Oct 29, 2021	BUY	$1.89 - $8.53 $567 - $2,559	300 New	300 $1,000

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $401M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.